Pasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory Diseases

Shares of Pasithea Therapeutics garnered heightened retail buzz on Tuesday after the firm announced preclinical results showing that its experimental drug, PAS-004, effectively blocked ETS2 signaling, which controls inflammation in IBD and other immune conditions.

Research from the Francis Crick Institute found PAS-004 more effective than selumetinib at reducing the expression of ETS2-regulated genes and macrophage functions essential for cytokine production and phagocytosis.

Pasithea Therapeutics shares ended Tuesday at $0.98, with a 3.77% gain, but they fell back 4.17% to $0.94 during after-hours trading.

According to Lee, who published a 2024 Nature paper identifying ETS2 as an essential regulator of IBD-related inflammation, the findings suggest PAS-004 could provide broader inhibition of inflammatory pathways compared to selumetinib and therapies that target individual cytokines or rely on JAK inhibition.

According to Pasithea CEO Tiago Reis Marques, data findings show PAS-004's potential for treating chronic inflammatory diseases and its existing cancer application. 

Safety data from Phase 1 trials in advanced cancer patients suggest that the drug appears to show good tolerance in wider therapeutic uses.

The firm announced its plan to move PAS-004 into proof-of-concept research targeting inflammatory disorders, including IBD and ankylosing spondylitis.

On Stocktwits, retail sentiment was ‘bullish’ amid a 7,450% surge in 24-hour message volume.

One user was “infuriated” after exiting a position in Pasithea Therapeutics (KTTA) at a loss after buying in at $1.18 and selling at $0.92, only to see the stock rise afterward.

Another user noted that Pasithea’s recent news was encouraging and pointed to the stock’s price movement from around $2.08 in April to $2.48 in early May as a sign of potential for organic upside.

The stock has declined 67% so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.